BeOne Medicines (ONC) Debt to Equity (2016 - 2025)
BeOne Medicines (ONC) has disclosed Debt to Equity for 11 consecutive years, with $0.01 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity fell 95.7% to $0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.01, a 95.7% decrease, with the full-year FY2025 number at $0.01, down 95.7% from a year prior.
- Debt to Equity was $0.01 for Q4 2025 at BeOne Medicines, down from $0.05 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.31 in Q4 2024 to a low of $0.01 in Q4 2025.
- A 5-year average of $0.13 and a median of $0.1 in 2021 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: skyrocketed 446.85% in 2024, then tumbled 95.7% in 2025.
- BeOne Medicines' Debt to Equity stood at $0.1 in 2021, then fell by 20.2% to $0.08 in 2022, then crashed by 31.82% to $0.06 in 2023, then surged by 446.85% to $0.31 in 2024, then crashed by 95.7% to $0.01 in 2025.
- Per Business Quant, the three most recent readings for ONC's Debt to Equity are $0.01 (Q4 2025), $0.05 (Q3 2025), and $0.25 (Q2 2025).